Wall Street analysts expect Chimerix, Inc. (NASDAQ:CMRX) to report earnings of ($0.41) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Chimerix’s earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.45). Chimerix reported earnings of ($0.39) per share in the same quarter last year, which indicates a negative year over year growth rate of 5.1%. The business is expected to report its next quarterly earnings results on Monday, August 14th.
On average, analysts expect that Chimerix will report full year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($1.99) to ($1.55). For the next fiscal year, analysts forecast that the company will report earnings of ($1.86) per share, with EPS estimates ranging from ($2.46) to ($1.49). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Chimerix.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.01. Chimerix had a negative return on equity of 24.07% and a negative net margin of 1,221.34%. The business had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.56 million.
Several equities research analysts recently issued reports on the company. Zacks Investment Research raised Chimerix from a “sell” rating to a “hold” rating in a research note on Monday. Cowen and Company reissued a “hold” rating and set a $6.00 price objective on shares of Chimerix in a research note on Friday, April 28th. Finally, FBR & Co reissued a “hold” rating and set a $7.00 price objective on shares of Chimerix in a research note on Monday, May 1st. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Chimerix currently has an average rating of “Hold” and an average target price of $7.55.
A number of large investors have recently modified their holdings of the company. Teza Capital Management LLC purchased a new stake in shares of Chimerix during the first quarter valued at about $135,000. American International Group Inc. raised its stake in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 1,733 shares during the period. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Chimerix during the first quarter valued at about $226,000. Trexquant Investment LP purchased a new stake in shares of Chimerix during the first quarter valued at about $226,000. Finally, Nationwide Fund Advisors raised its stake in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 1,977 shares during the period. 66.76% of the stock is owned by hedge funds and other institutional investors.
Chimerix (NASDAQ CMRX) traded up 0.676% during trading on Thursday, hitting $5.215. The stock had a trading volume of 124,140 shares. The stock’s market capitalization is $243.28 million. The company has a 50-day moving average of $4.93 and a 200-day moving average of $5.38. Chimerix has a 52 week low of $3.66 and a 52 week high of $6.64.
TRADEMARK VIOLATION NOTICE: “Chimerix, Inc. (NASDAQ:CMRX) Expected to Announce Earnings of -$0.41 Per Share” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2017/08/05/chimerix-inc-nasdaqcmrx-expected-to-announce-earnings-of-0-41-per-share-updated-updated.html.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Get a free copy of the Zacks research report on Chimerix (CMRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
